Zealand Pharma

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Novo Nordisk Licenses Zealand’s Diabetes Treatment

Denmark’s Novo Nordisk has entered into a global license and development with compatriot biotech Zealand Pharma for the latter’s Zegalogue (dasiglucagon) injectable diabetes treatment.

Sanofi Aims to Expand in Diabetes Market